Cardiovascular Disease Protection Tissue

Summary

Recent evidence of a potential role for cardiac progenitor cells (CPCs) in cardiac repair and the discovery of a vasoprotective axis of the renin-angiotensin system (RAS) offer such breakthroughs. Investigators have observed that an imbalance in the vasoprotective axis {angiotensin converting enzyme 2 (ACE2)/angiotensin-(1-7) \[Ang-(1-7)\]/Mas receptor} and the vasodeleterious axis \[angiotensin converting enzyme (ACE)/angiotensin II (AngII)/AngII type 1 receptor (AT1R)\] of the RAS within the CPCs affects their functionality and regenerative potential. Investigators believe that restoring the balance between these two axes of the RAS is essential to improve CPC function and enhance their reparative capabilities. These observations have led to the hypothesis that genetic modification of CPCs by overexpression of ACE2/Ang-(1-7) will enhance their reparative function and improve their potential to attenuate myocardial ischemia-induced cardiac damage.

Conditions

• Myocardial Ischemia

Interventions

PROCEDURE

Heart failure or coronary disease

Small samples collected from the apex core in the heart. In addition, blood samples will be taken.

PROCEDURE

Heart transplant patients

Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.

PROCEDURE

Orthotopic Heart Transplant Patients

Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.

PROCEDURE

Heart Surgery Patients

Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.

PROCEDURE

Blood Draw

All subjects will have 20 ml of blood drawn for further analysis.

Sponsors & Collaborators

• National Institutes of Health (NIH)

  collaborator NIH

• National Heart, Lung, and Blood Institute (NHLBI)

  collaborator NIH

• University of Florida

  lead OTHER

Principal Investigators

• Carl J Pepine, MD · University of Florida

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2013-06-30

Primary Completion

2018-09-28

Completion

2018-09-28

Countries

• United States

Study Locations